NDA 018421 · Hikma
Lithium Citrate
Lithium Citrate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1980
Dec 23, 1980
Approved uses
1
Original approval plus efficacy supplements
Registered trials
246
60 Phase 3, 16 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- LITHIUM CITRATE · LITHIUM CITRATE EQ 300MG CARBONATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SYRUP, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Lithium" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00261443 · 1,270 participants · Start Sep 2005 · Primary completion Jun 2009
Drug: Lithium or Valproate with placebo (PBO); Lithium or Valproate with Aripiprazole · For: Bipolar Disorder
Sites: Tuscaloosa, Alabama; Anaheim, California; Cerritos, California · 83 sites in all
- Quetiapine Fumarate Bipolar Maintenance MonotherapyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00314184 · 1,255 participants · Start Mar 2005
Drug: quetiapine fumarate · For: Bipolar Disorder
Sites: Cerritos, California; San Diego, California; Santa Ana, California · 95 sites in all
- Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01358357 · 965 participants · Start Jun 2011 · Primary completion Apr 2015
Drug: Lurasidone; Placebo · For: Bipolar I Disorder
Sites: Dothan, Alabama; Glendale, California; Los Angeles, California · 105 sites in all
- The Early Medication Change (EMC) TrialPivotal-lookingCompleted
K. LiebAcademic, hospital or other
NCT00974155 · 889 participants · Start Sep 2009 · Primary completion May 2014
Drug: Escitalopram, venlafaxine, lithium; Escitalopram, venlafaxine · For: Depression
Sites: Mainz, Germany
- Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological CharacteristicsPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT03219008 · 800 participants (planned) · Start Aug 1, 2017 · Primary completion Dec 2019
Drug: Fluoxetine; fluoxetine + Amfebutamone and 4 more · For: Depressive Disorder
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lithium Citrate (Lithium Citrate)
2024 spending
$139K
Beneficiaries
327
1,009 claims
Per beneficiary
$424
$0.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,375 |
| 2024 | $138,521 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I, Kodama W · Ageing Res Rev 2024 · Comparative Study, Systematic Review
- Lithium toxicity profile: a systematic review and meta-analysis.
McKnight RF, Adida M, Budge K, et al. · Lancet 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease.
Singulani MP, Ferreira AFF, Figueroa PS, et al. · Ageing Res Rev 2024 · Meta-Analysis, Systematic Review
- Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis.
Huang Q, Ma XQ, Chen HF · J Clin Psychopharmacol 2024 · Systematic Review, Meta-Analysis
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.